Nippon India PHARMA Fund - G

NAV ₹349.301 ↑ 0.24 (0.07 %) as on 22 Aug 23

Table of Contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.3% since its launch. Ranked 35 in Sectoral category. Return for 2022 was -9.9% , 2021 was 23.9% and 2020 was 66.4% .

Below is the key information for Nippon India Pharma Fund

NAV as on 22 Aug 23	₹349.301 ↑ 0.24 (0.07 %)
Net Assets (AUM) as on 31 Jul 2023	₹5,392 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	2.26
Expense Ratio	1.97 %
Sharpe Ratio	1.198
Information Ratio	0.62
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 22 Aug 23

Duration	Returns
1 Month	5.6%
3 Month	24.7%
6 Month	29.2%
1 Year	27.3%
3 Year	16.2%
5 Year	17.5%
10 Year
15 Year
Since launch	20.3%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2022	-9.9%
2021	23.9%
2020	66.4%
2019	1.7%
2018	3.6%
2017	7.6%
2016	-10.6%
2015	19.4%
2014	49.5%

Growth of 10k Over Years

Date	Value
31 Aug 18	₹10,000
31 Aug 19	₹8,733
31 Aug 20	₹13,180
31 Aug 21	₹19,501
31 Aug 22	₹17,099
31 Aug 23	₹21,433

Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset Class	Value
Cash	3.22%
Equity	96.78%

Sector Allocation

Sector	Value
Health Care	96.78%

Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	13%	₹729 Cr	6,556,349
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| 500257	Drug Manufacturers - Specialty & Generic	8%	₹418 Cr	3,803,676 ↓ -200,000
Cipla Ltd Shs Dematerialised (Healthcare) Equity, Since 31 May 08 \| 500087	Drug Manufacturers - General	7%	₹377 Cr	3,000,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	Drug Manufacturers - Specialty & Generic	6%	₹308 Cr	550,030
Gland Pharma Ltd (Healthcare) Equity, Since 30 Nov 20 \| GLAND	Drug Manufacturers - General	5%	₹261 Cr	1,500,000 ↑ 300,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	5%	₹252 Cr	700,808
Medplus Health Services Ltd (Healthcare) Equity, Since 30 Nov 22 \| 543427	Pharmaceutical Retailers	5%	₹250 Cr	3,076,603 ↑ 1,160,000
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Dec 15 \| AUROPHARMA	Drug Manufacturers - Specialty & Generic	4%	₹208 Cr	2,500,000 ↓ -500,000
J.B. Chemicals & Pharmaceuticals Ltd Shs Dematerialised (Healthcare) Equity, Since 31 Jan 22 \| JBCHEPHARM	Drug Manufacturers - Specialty & Generic	4%	₹207 Cr	748,446 ↓ -10,132
Zydus Lifesciences Ltd (Healthcare) Equity, Since 31 Jan 18 \| 532321	Drug Manufacturers - Specialty & Generic	4%	₹200 Cr	3,200,835

1 - 10 of 33

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	18.43 Yr.
Kinjal Desai	25 May 18	5.27 Yr.
Akshay Sharma	1 Dec 22	0.75 Yr.

Custodians

Company	Address
Deutsche Bank AG	Deutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
Address	KFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX	91-40-23311968
Email	mailmanager@karvy.com

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹96.9949 ↑ 0.07	29.22 %	27.26 %	20.83 %	19.83 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹96.9949 ↑ 0.07	29.22 %	27.26 %	20.83 %	19.83 %
Nippon India Pharma Fund Growth	₹349.301 ↑ 0.24	29.22 %	27.26 %	16.16 %	17.49 %
Data as on 22 Aug 23

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.